KRAS and non-small cell lung carcinoma: More than 95% of KRAS gene mutations associated with NSCLC oncogenesis display changes in glycine at position 12 or 13 (Gly12 or Gly13) or glutamine at position 61 (Gln61) in the KRAS protein (Aviel‐Ronen et al, 2006).